½ÃÀ庸°í¼­
»óǰÄÚµå
1459787

¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2031³â)

Multiplex Assays Market (Product: Instruments, Consumables, and Software; and Technology: Multiplex RT-PCR, Flow Cytometry, Fluorescence, and Luminescence) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 333 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå - Á¶»ç ¹üÀ§

TMRÀÇ Á¶»ç º¸°í¼­ "¼¼°è ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå"Àº 2023³âºÎÅÍ 2031³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾ò±â À§ÇØ °ú°Å»Ó¸¸ ¾Æ´Ï¶ó ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ Á¶»çÇÏ¿© 2023³âÀ» ±âÁØ ¿¬µµ·Î, 2031³âÀ» ¿¹Ãø ¿¬µµ·Î »ï°í ÀÖ½À´Ï´Ù. 2017³âºÎÅÍ 2031³â±îÁö ¼¼°è ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀÇ ¼öÀͰú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ 2023³âºÎÅÍ 2031³â±îÁö ¼¼°è ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR%)µµ Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ ÅëÇØ ÀÛ¼ºµÇ¾úÀ¸¸ç, 1Â÷ Á¶»ç¿¡¼­´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ ¹× ¿ÀÇǴϾð Á¦Á¶¾÷ü¸¦ ÀÎÅͺäÇϰí, 2Â÷ Á¶»ç¿¡¼­´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼­, º¸µµ ÀÚ·á, °ü·Ã ¹®¼­ µîÀ» ÂüÁ¶ÇÏ¿© ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀ» ÆÄ¾ÇÇß½À´Ï´Ù, ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀ» ÆÄ¾ÇÇß½À´Ï´Ù.

½ÃÀå ÇöȲ
2022³â ½ÃÀå °¡Ä¡ 32¾ï ´Þ·¯
2031³â ½ÃÀå °¡Ä¡ 59¾ï ´Þ·¯
CAGR 6.9%

ÀÌ º¸°í¼­´Â ¼¼°è ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀÇ °æÀï ȯ°æÀ» Á¶»çÇß½À´Ï´Ù. ¼¼°è ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÌ È®ÀεǾúÀ¸¸ç, °¢ ±â¾÷µéÀº ´Ù¾çÇÑ ¼Ó¼ºÀ¸·Î ÇÁ·ÎÆÄÀϸµµÇ¾ú½À´Ï´Ù. ±â¾÷ °³¿ä, À繫 »óÅÂ, ÃÖ±Ù ½ÃÀå °³¹ß, SWOT´Â ÀÌ º¸°í¼­¿¡ ¼Ò°³µÈ ¼¼°è ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½ÃÀåÀÇ ±â¾÷ ¼Ó¼ºÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼­·Ð
  • ½ÃÀå °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø, 2017-2031³â

Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ÁÖ¿ä Á¦Ç°/ºê·£µå ºÐ¼®
  • ÁÖ¿ä M&A
  • COVID-19 ÆÒµ¥¹ÍÀÇ »ê¾÷¿¡ ´ëÇÑ ¿µÇâ

Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Ç°º°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : Á¦Ç°º°, 2017-2031
    • ±â±¸
    • ¼Ò¸ðǰ
      • ½Ã¾à ¹× ŰƮ
      • ¸¶ÀÌÅ©·ÎÇÇÆê ¹× ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ®
      • ±âŸ
    • ¼ÒÇÁÆ®¿þ¾î
  • ½ÃÀåÀÇ ¸Å·Â : Á¦Ç°º°

Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ±â¼úº°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ±â¼úº°, 2017³â-2031³â
    • ¸ÖƼÇ÷º½º RT-PCR
    • À¯¼¼Æ÷ºÐ¼®±â
    • ¹ß±¤
    • Çü±¤
    • ±âŸ
    • ½ÃÀåÀÇ ¸Å·Â : ±â¼úº°

Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çüº°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : À¯Çüº°, 2017³â-2031³â
    • ´Ü¹éÁú
      • . Planar
      • ºñÁî ±â¹Ý
    • ÇÙ»ê
      • . Planar
      • ºñÁî ±â¹Ý
    • ¼¼Æ÷
  • ½ÃÀåÀÇ ¸Å·Â : À¯Çüº°

Á¦9Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿ëµµº°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ¿ëµµº°, 2017-2031³â
    • ¿¬±¸°³¹ß
      • Drug Discovery & Research
      • ¹ÙÀÌ¿À ¸¶Ä¿ ¿¬±¸ ¹× ÀÀ¿ë
    • Áø´Ü
      • °¨¿°Áõ
      • ÀÚ°¡¸é¿ªÁúȯ
      • ¾Ï
      • ½ÉÇ÷°üÁúȯ
      • ½Å°æ³»ºÐºñÁúȯ
      • ±âŸ
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â : ¿ëµµº°

Á¦10Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2017³â-2031³â
    • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹× ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
    • Çмú ¹× ¿¬±¸¼¾ÅÍ
    • Áø´Ü¼¾ÅÍ
    • º´¿ø
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : Áö¿ªº°, 2017³â-2031³â
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â : Áö¿ªº°

Á¦12Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦13Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦14Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦15Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦16Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦17Àå °æÀï ±¸µµ

  • ½ÃÀå °æÀï ¸ÅÆ®¸¯½º(±â¾÷ Tierº°¡¤±â¾÷ ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2022³â)
  • ±â¾÷ °³¿ä
    • DiaSorin S.p.A.
    • Thermo Fisher Scientific, Inc.
    • Seegene, Inc.
    • Meso Scale Diagnostics, LLC
    • Abcam Limited
    • QIAGEN
    • Bio-Rad Laboratories, Inc.
    • Merck KGaA
    • Quansys Biosciences
    • Illumina, Inc.
LSH 24.05.17

Multiplex Assays Market - Scope of Report

TMR's report on the global multiplex assayss market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global multiplex assayss market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global multiplex assayss market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the multiplex assayss market.

Market Snapshot
Market Value in 2022US$ 3.2 Bn
Market Value in 2031US$ 5.9 Bn
CAGR6.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global multiplex assayss market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global multiplex assayss market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global multiplex assayss market.

The report delves into the competitive landscape of the global multiplex assayss market. Key players operating in the global multiplex assayss market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global multiplex assayss market profiled in this report.

Key Questions Answered in Global multiplex assayss Market Report:

  • What is the sales/revenue generated by multiplex assayss across all regions during the forecast period?
  • What are the opportunities in the global multiplex assayss market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Multiplex Assays Market - Research Objectives and Research Approach

The comprehensive report on the global multiplex assayss market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global multiplex assayss market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global multiplex assayss market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Multiplex Assays Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Multiplex Assays Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Multiplex Assays Market Analysis and Forecast, by Product

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product, 2017-2031
    • 6.3.1. Instruments
    • 6.3.2. Consumables
      • 6.3.2.1. Reagents & Kits
      • 6.3.2.2. Micropipettes & Microplates
      • 6.3.2.3. Others
    • 6.3.3. Software
  • 6.4. Market Attractiveness, by Product

7. Global Multiplex Assays Market Analysis and Forecast, by Technology

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Technology, 2017-2031
    • 7.3.1. Multiplex RT-PCR
    • 7.3.2. Flow Cytometry
    • 7.3.3. Luminescence
    • 7.3.4. Fluorescence
    • 7.3.5. Others
    • 7.3.6. Market Attractiveness, by Technology

8. Global Multiplex Assays Market Analysis and Forecast, By Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, By Type, 2017-2031
    • 8.3.1. Protein
      • 8.3.1.1. Planar
      • 8.3.1.2. Bead-based
    • 8.3.2. Nucleic Acid
      • 8.3.2.1. Planar
      • 8.3.2.2. Bead-based
    • 8.3.3. Cell
  • 8.4. Market Attractiveness, By Type

9. Global Multiplex Assays Market Analysis and Forecast, by Application

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Application, 2017-2031
    • 9.3.1. Research & Development
      • 9.3.1.1. Drug Discovery & Research
      • 9.3.1.2. Biomarker Research & Application
    • 9.3.2. Diagnosis
      • 9.3.2.1. Infectious Diseases
      • 9.3.2.2. Autoimmune Diseases
      • 9.3.2.3. Cancer
      • 9.3.2.4. Cardiovascular Diseases
      • 9.3.2.5. Neuroendocrine Diseases
      • 9.3.2.6. Others
    • 9.3.3. Others
  • 9.4. Market Attractiveness, by Application

10. Global Multiplex Assays Market Analysis and Forecast, by End-user

  • 10.1. Introduction and Definitions
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by End-user, 2017-2031
    • 10.3.1. Biotechnology & Biopharmaceutical Companies
    • 10.3.2. Academic & Research Centers
    • 10.3.3. Diagnostic Centers
    • 10.3.4. Hospitals
    • 10.3.5. Others
  • 10.4. Market Attractiveness, by End-user

11. Global Multiplex Assays Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2017-2031
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness, by Region

12. North America Multiplex Assays Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Instruments & Software
    • 12.2.2. Kits & Reagents
    • 12.2.3. Services
  • 12.3. Market Attractiveness, by Product
  • 12.4. Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. Conventional PCR
    • 12.4.2. Singleplex PCR
    • 12.4.3. Multiplex PCR
    • 12.4.4. Real-time PCR
    • 12.4.5. Others
  • 12.5. Market Attractiveness, by Technology
  • 12.6. Market Value Forecast, By Type, 2017-2031
    • 12.6.1. Protein
      • 12.6.1.1. Planar
      • 12.6.1.2. Bead-based
    • 12.6.2. Nucleic Acid
      • 12.6.2.1. Planar
      • 12.6.2.2. Bead-based
    • 12.6.3. Cell
  • 12.7. Market Attractiveness, By Type
  • 12.8. Market Value Forecast, by Application, 2017-2031
    • 12.8.1. Companion Animal
    • 12.8.2. Livestock Animal
  • 12.9. Market Attractiveness, by Application
  • 12.10. Market Value Forecast, by End-user, 2017-2031
    • 12.10.1. Biotechnology & Biopharmaceutical Companies
    • 12.10.2. Academic & Research Centers
    • 12.10.3. Diagnostic Centers
    • 12.10.4. Hospitals
    • 12.10.5. Others
  • 12.11. Market Attractiveness, by End-user
  • 12.12. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.12.1. U.S.
    • 12.12.2. Canada
  • 12.13. Market Attractiveness Analysis
    • 12.13.1. By Product
    • 12.13.2. By Technology
    • 12.13.3. By Type
    • 12.13.4. By Application
    • 12.13.5. By End-user
    • 12.13.6. By Country

13. Europe Multiplex Assays Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Instruments
    • 13.2.2. Consumables
      • 13.2.2.1. Reagents & Kits
      • 13.2.2.2. Micropipettes & Microplates
      • 13.2.2.3. Others
    • 13.2.3. Software
  • 13.3. Market Attractiveness, by Product
  • 13.4. Market Value Forecast, by Technology, 2017-2031
    • 13.4.1. Multiplex RT-PCR
    • 13.4.2. Flow Cytometry
    • 13.4.3. Luminescence
    • 13.4.4. Fluorescence
    • 13.4.5. Others
  • 13.5. Market Attractiveness, by Technology
  • 13.6. Market Value Forecast, By Type, 2017-2031
    • 13.6.1. Protein
      • 13.6.1.1. Planar
      • 13.6.1.2. Bead-based
    • 13.6.2. Nucleic Acid
      • 13.6.2.1. Planar
      • 13.6.2.2. Bead-based
    • 13.6.3. Cell
  • 13.7. Market Attractiveness, By Type
  • 13.8. Market Value Forecast, by Application, 2017-2031
    • 13.8.1. Research & Development
      • 13.8.1.1. Drug Discovery & Research
      • 13.8.1.2. Biomarker Research & Application
    • 13.8.2. Diagnosis
      • 13.8.2.1. Infectious Diseases
      • 13.8.2.2. Autoimmune Diseases
      • 13.8.2.3. Cancer
      • 13.8.2.4. Cardiovascular Diseases
      • 13.8.2.5. Neuroendocrine Diseases
      • 13.8.2.6. Others
    • 13.8.3. Others
  • 13.9. Market Attractiveness, by Application
  • 13.10. Market Value Forecast, by End-user, 2017-2031
    • 13.10.1. Biotechnology & Biopharmaceutical Companies
    • 13.10.2. Academic & Research Centers
    • 13.10.3. Diagnostic Centers
    • 13.10.4. Hospitals
    • 13.10.5. Others
  • 13.11. Market Attractiveness, by End-user
  • 13.12. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.12.1. Germany
    • 13.12.2. U.K.
    • 13.12.3. France
    • 13.12.4. Italy
    • 13.12.5. Spain
    • 13.12.6. Rest of Europe
  • 13.13. Market Attractiveness Analysis
    • 13.13.1. By Product
    • 13.13.2. By Technology
    • 13.13.3. By Type
    • 13.13.4. By Application
    • 13.13.5. By End-user
    • 13.13.6. By Country/Sub-region

14. Asia Pacific Multiplex Assays Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2017-2031
    • 14.2.1. Instruments
    • 14.2.2. Consumables
      • 14.2.2.1. Reagents & Kits
      • 14.2.2.2. Micropipettes & Microplates
      • 14.2.2.3. Others
    • 14.2.3. Software
  • 14.3. Market Attractiveness, by Product
  • 14.4. Market Value Forecast, by Technology, 2017-2031
    • 14.4.1. Multiplex RT-PCR
    • 14.4.2. Flow Cytometry
    • 14.4.3. Luminescence
    • 14.4.4. Fluorescence
    • 14.4.5. Others
  • 14.5. Market Attractiveness, by Technology
  • 14.6. Market Value Forecast, By Type, 2017-2031
    • 14.6.1. Protein
      • 14.6.1.1. Planar
      • 14.6.1.2. Bead-based
    • 14.6.2. Nucleic Acid
      • 14.6.2.1. Planar
      • 14.6.2.2. Bead-based
    • 14.6.3. Cell
  • 14.7. Market Attractiveness, By Type
  • 14.8. Market Value Forecast, by Application, 2017-2031
    • 14.8.1. Research & Development
      • 14.8.1.1. Drug Discovery & Research
      • 14.8.1.2. Biomarker Research & Application
    • 14.8.2. Diagnosis
      • 14.8.2.1. Infectious Diseases
      • 14.8.2.2. Autoimmune Diseases
      • 14.8.2.3. Cancer
      • 14.8.2.4. Cardiovascular Diseases
      • 14.8.2.5. Neuroendocrine Diseases
      • 14.8.2.6. Others
    • 14.8.3. Others
  • 14.9. Market Attractiveness, by Application
  • 14.10. Market Value Forecast, by End-user, 2017-2031
    • 14.10.1. Biotechnology & Biopharmaceutical Companies
    • 14.10.2. Academic & Research Centers
    • 14.10.3. Diagnostic Centers
    • 14.10.4. Hospitals
    • 14.10.5. Others
  • 14.11. Market Attractiveness, by End-user
  • 14.12. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.12.1. China
    • 14.12.2. Japan
    • 14.12.3. India
    • 14.12.4. Australia & New Zealand
    • 14.12.5. Rest of Asia Pacific
  • 14.13. Market Attractiveness Analysis
    • 14.13.1. By Product
    • 14.13.2. By Technology
    • 14.13.3. By Type
    • 14.13.4. By Application
    • 14.13.5. By End-user
    • 14.13.6. By Country/Sub-region

15. Latin America Multiplex Assays Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Product, 2017-2031
    • 15.2.1. Instruments
    • 15.2.2. Consumables
      • 15.2.2.1. Reagents & Kits
      • 15.2.2.2. Micropipettes & Microplates
      • 15.2.2.3. Others
    • 15.2.3. Software
  • 15.3. Market Attractiveness, by Product
  • 15.4. Market Value Forecast, by Technology, 2017-2031
    • 15.4.1. Multiplex RT-PCR
    • 15.4.2. Flow Cytometry
    • 15.4.3. Luminescence
    • 15.4.4. Fluorescence
    • 15.4.5. Others
  • 15.5. Market Attractiveness, by Technology
  • 15.6. Market Value Forecast, By Type, 2017-2031
    • 15.6.1. Protein
      • 15.6.1.1. Planar
      • 15.6.1.2. Bead-based
    • 15.6.2. Nucleic Acid
      • 15.6.2.1. Planar
      • 15.6.2.2. Bead-based
    • 15.6.3. Cell
  • 15.7. Market Attractiveness, By Type
  • 15.8. Market Value Forecast, by Application, 2017-2031
    • 15.8.1. Research & Development
      • 15.8.1.1. Drug Discovery & Research
      • 15.8.1.2. Biomarker Research & Application
    • 15.8.2. Diagnosis
      • 15.8.2.1. Infectious Diseases
      • 15.8.2.2. Autoimmune Diseases
      • 15.8.2.3. Cancer
      • 15.8.2.4. Cardiovascular Diseases
      • 15.8.2.5. Neuroendocrine Diseases
      • 15.8.2.6. Others
    • 15.8.3. Others
  • 15.9. Market Attractiveness, by Application
  • 15.10. Market Value Forecast, by End-user, 2017-2031
    • 15.10.1. Biotechnology & Biopharmaceutical Companies
    • 15.10.2. Academic & Research Centers
    • 15.10.3. Diagnostic Centers
    • 15.10.4. Hospitals
    • 15.10.5. Others
  • 15.11. Market Attractiveness, by End-user
  • 15.12. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.12.1. Brazil
    • 15.12.2. Mexico
    • 15.12.3. Rest of Latin America
  • 15.13. Market Attractiveness Analysis
    • 15.13.1. By Product
    • 15.13.2. By Technology
    • 15.13.3. By Type
    • 15.13.4. By Application
    • 15.13.5. By End-user
    • 15.13.6. By Country/Sub-region

16. Middle East & Africa Multiplex Assays Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Product, 2017-2031
    • 16.2.1. Instruments
    • 16.2.2. Consumables
      • 16.2.2.1. Reagents & Kits
      • 16.2.2.2. Micropipettes & Microplates
      • 16.2.2.3. Others
    • 16.2.3. Software
  • 16.3. Market Attractiveness, by Product
  • 16.4. Market Value Forecast, by Technology, 2017-2031
    • 16.4.1. Multiplex RT-PCR
    • 16.4.2. Flow Cytometry
    • 16.4.3. Luminescence
    • 16.4.4. Fluorescence
    • 16.4.5. Others
  • 16.5. Market Attractiveness, by Technology
  • 16.6. Market Value Forecast, By Type, 2017-2031
    • 16.6.1. Protein
      • 16.6.1.1. Planar
      • 16.6.1.2. Bead-based
    • 16.6.2. Nucleic Acid
      • 16.6.2.1. Planar
      • 16.6.2.2. Bead-based
    • 16.6.3. Cell
  • 16.7. Market Attractiveness, By Type
  • 16.8. Market Value Forecast, by Application, 2017-2031
    • 16.8.1. Research & Development
      • 16.8.1.1. Drug Discovery & Research
      • 16.8.1.2. Biomarker Research & Application
    • 16.8.2. Diagnosis
      • 16.8.2.1. Infectious Diseases
      • 16.8.2.2. Autoimmune Diseases
      • 16.8.2.3. Cancer
      • 16.8.2.4. Cardiovascular Diseases
      • 16.8.2.5. Neuroendocrine Diseases
      • 16.8.2.6. Others
    • 16.8.3. Others
  • 16.9. Market Attractiveness, by Application
  • 16.10. Market Value Forecast, by End-user, 2017-2031
    • 16.10.1. Biotechnology & Biopharmaceutical Companies
    • 16.10.2. Academic & Research Centers
    • 16.10.3. Diagnostic Centers
    • 16.10.4. Hospitals
    • 16.10.5. Others
  • 16.11. Market Attractiveness, by End-user
  • 16.12. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.12.1. GCC Countries
    • 16.12.2. South Africa
    • 16.12.3. Rest of Middle East & Africa
  • 16.13. Market Attractiveness Analysis
    • 16.13.1. By Product
    • 16.13.2. By Technology
    • 16.13.3. By Type
    • 16.13.4. By Application
    • 16.13.5. By End-user
    • 16.13.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 17.2. Market Share Analysis, by Company (2022)
  • 17.3. Company Profiles
    • 17.3.1. DiaSorin S.p.A.
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. Thermo Fisher Scientific, Inc.
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. Seegene, Inc.
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Meso Scale Diagnostics, LLC
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. Abcam Limited
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. QIAGEN
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. Bio-Rad Laboratories, Inc.
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Merck KGaA
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Quansys Biosciences
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. Illumina, Inc.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦